Uncategorized

Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promise

Published

4 days ago

on

Allogene Therapeutics’ CAR-T therapy removed all remaining detectable lymphoma cells in just over half of treated patients, according to an early look at the Phase 2 data.

The Bay Area biotech …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version